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Abstract
An increase in off-season (June to September) 
Ross River virus (RRV) notifications from the greater 
Perth metropolitan area was observed from 2006 
to 2009. We investigated the increase to determine 
whether it is likely to have reflected a true increase 
in off-season cases. A single positive RRV IgM test 
result is sufficient for RRV notification but where 
follow-up testing was performed, the positive pre-
dictive value of an IgM test where IgG was nega-
tive was very low in the off-season and also in the 
season when using the only commercially available 
test kit. The increase in off-season notifications was 
not associated with an increase in off-season test-
ing. Some Perth laboratories use more stringent 
notification criteria than the nationally agreed RRV 
case definition, and the geographical distribution 
of samples tested varies between laboratories. 
Our findings make a strong case to change the 
nationally agreed case definition for RRV to not 
accept a single IgM positive test result as labora-
tory definitive evidence where the IgG is negative. 
Our study also identified a range of challenges in 
interpreting changes in seasonal patterns and geo-
graphical distribution of RRV. Any such observed 
changes should be investigated through further 
data analysis and/or mosquito trapping and test-
ing in order to assess validity. Commun Dis Intell 
2014;38(2):E115–E122.
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Introduction
Ross River virus (RRV) is a mosquito-borne 
alphavirus infection that occurs throughout 
Australia and the South Pacific.1,2 It causes an 
acute illness characterised by joint pain, arthritis, 
fatigue and malaise, often accompanied by fever 
and a rash. While not life-threatening, RRV can 
cause significant morbidity, with symptoms lasting 
up to 6 months.1–3
RRV is a nationally notifiable disease. Laboratories 
and treating doctors are required to report to the 
Western Australian Department of Health (WA 
Health), all cases of RRV infection meeting the 
nationally agreed case definition.4 In Western 
Australia, notifications are recorded in the 
Western Australian Notifiable Infectious Diseases 
Database (WANIDD). The serological component 
of the case definition is: RRV-IgG seroconversion 
or a fourfold rise in RRV-IgG between acute and 
convalescent samples; detection of RRV IgG and 
IgM in a single sample; or detection of RRV-IgM 
without IgG when there is no detectable IgM to 
Barmah Forest virus (BFV).
From 2006 onwards, all laboratories in Western 
Australia were legislatively required to directly notify 
cases. Prior to that date, notifiable diseases were 
notified by doctors based on clinical and/or labora-
tory diagnoses, and in the early 2000s by the only 
public sector testing laboratory (PathWest Laboratory 
Medicine WA) and some private laboratories.
Local governments and the Environmental Health 
Directorate of WA Health undertake enhanced 
surveillance of RRV cases notified by treating doc-
tors, to identify the most likely place of exposure 
and date of onset of symptoms. This information is 
recorded in the Mosquito Borne Disease Control 
(MBDC) database.
In the south-west of Western Australia, RRV 
typically causes outbreaks of varying sizes between 
October and May. In 2006 it was observed that the 
number of RRV notifications reported during the 
off-season (June to September) were higher than 
expected in the Perth Metropolitan region and the 
Peel region immediately south of Perth (Figure 1).
In Western Australia, RRV notifications are used to 
identify areas of high RRV activity to enable addi-
tional mosquito control activity and public warnings. 
Notification data are complemented by mosquito 
surveillance in areas of historically high activity over 
summer. A change in the distribution of RRV cases to 
include the off-season in the south-west is potentially 
very important as it could flag changes in the ecol-
ogy of vector mosquitoes and animal hosts. This has 
implications for human health and for risk mitigation 
activities such as mosquito control.
This study examined the notification data and 
laboratory testing data, assessing whether the 
notifications reflected a real increase in off-season 
RRV cases or an artefact of testing and/or notifica-
tion practices.
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Methods
This was a descriptive study.
Notification rates
RRV notifications for the Perth Metropolitan and 
Peel regions by laboratory, month and year of 
onset from 1 January 1990 to 30 June 2012 were 
retrieved from WANIDD. Population data at 
Statistical Local Area level were obtained from 
the Australian Bureau of Statistics and aggre-
gated into MBDC regions. Notification rates per 
100,000 population were calculated by dividing the 
number of notifications in that time period by the 
estimated population for that year and multiplying 
by 100,000, and were annualised by multiplying 
the rate by 12 divided by the number of months.
Enhanced surveillance data
Notification data by month and year of onset and 
region of acquisition as documented by enhanced 
surveillance were retrieved from the MBDC 
database for the years 2006 to 2009 inclusive. 
The enhanced surveillance data were compared 
with the notification data to assess whether hav-
ing further information about the onset date and 
likely place of acquisition of infection changed the 
proportion of off-season notifications in the Perth 
Metropolitan and Peel regions.
Laboratory testing
Laboratory testing data for the Perth Metropolitan 
and Peel regions for the period from 1 January 
2002 to 31 August 2012 were obtained from 
PathWest Laboratory Medicine WA (PathWest) 
and St John of God Pathology (SJGP). PathWest 
is the state reference laboratory. It uses an in-house 
immunofluorescence assay (IFA) for the detection 
of IgM antibodies,5 and an in-house haemagglu-
tination inhibition (HI) test.6 The latter detects 
both IgG and IgM together and is less sensitive 
than the IFA for detection of IgM.6 The in-house 
assays have been validated according to guidelines 
published by the National Pathology Accreditation 
Advisory Council, and have been approved for 
diagnostic use by the National Association of 
Testing Authorities. The sensitivity and specificity 
of these tests is not known. Both tests are routinely 
performed on samples referred for RRV diagnosis. 
All but one laboratory (which refers their samples 
to PathWest), including SJGP, use a commercial 
enzyme immunoassay (EIA); Panbio® RRV IgM 
ELISA and Panbio® RRV IgG ELISA (Alere, 
Sinnamon Park, Queensland Australia). The sen-
sitivity and specificity of these tests was estimated 
in South Australia by testing samples taken in 1996 
and 1997 using an HI test as the comparator. The 
sensitivity of the PanBio ELISA kits was estimated 
to be 98.5% and 84.6% and the specificity 96.5% 
and 97.6% for IgM and IgG respectively.7 These 
are the only commercial tests currently available in 
Australia. In response to a doctor’s request for RRV 
serology, all private laboratories test separately for 
IgM and IgG antibodies.
PathWest routinely requests second samples where 
the sample is IgM positive within 2 weeks of onset of 
illness independent of the HI test result. This allows 
detection of seroconversion or a significant rise in 
IgG using the HI tests to confirm acute infection. 
SJGP requests second samples where the initial IgM 
is positive but the IgG is negative in order to test 
for seroconversion. The EIA tests do not quantify 
results and cannot be routinely used to detect rises 
in IgG, but will detect seroconversion.
A more detailed analysis of positive IgM results was 
carried out for patients from the Perth Metropolitan 
and Peel regions. Patients who had results for more 
than 1 sample were identified and the results were 
used to assess the interpretation of the first IgM 
positive sample for each patient. (Table 1).
Notification practices of the laboratories
The three private laboratories (SJGP and 
Laboratory B and C) and PathWest who, combined, 
notify the majority of RRV cases, were contacted to 
ask about their notification practices for RRV.
Table 1: Classification of Ross River virus IgM positive test results following follow-up testing
Classification PathWest Private
True positive Seroconversion from negative IgG (HI <40) to 
positive OR HI ≥40 and a fourfold or greater rise in 
HI titre between acute and convalescent samples 
OR HI ≥40 on first and second samples
IgM with IgG seroconversion OR IgM and IgG 
positive on initial and a later sample
False positive HI ≤40 on second sample seven or more days 
after the first test OR IgM becomes negative within 
6 months of the first test OR patient is known to 
have past Ross River virus infection
IgG negative on repeat testing seven or more days 
after the first positive IgM test OR IgM becomes 
negative within 6 months of the first test
The positive predictive value of the test was calculated by the formula: true positive/(true positive + false positive).
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Data analysis
Data were analysed for Perth Metropolitan and 
Peel regions. Comparisons between means were 
performed using Independent t tests. Analysis was 
undertaken using Microsoft Excel and SPSS ver-
sion 21 software.
Results
Notification rates
There were 6,337 RRV notifications from Perth 
Metropolitan and Peel regions from 1 January 
1990 to 30 June 2012. The population in the Perth 
Metropolitan region in 2012 was 1.6 million people 
and in the Peel region was 236,000. The notifica-
tion rates in the off-season in Perth Metropolitan 
and Peel regions were higher in the years between 
2006 and 2009 compared to the other years (mean 
of 11.6 vs 2.4 for the Perth Metropolitan region; 
37.6 vs 10.6 for the Peel region (P<0.05)), but there 
was no significant difference in the notification 
rates during the season for the 2006 to 2009 period 
compared with the other years (mean of 23.4 vs 18.3 
for the Perth Metropolitan region; 88.7 vs 59.6 for 
the Peel region (P>0.05)) (Figure 1 and Figure 2).
Enhanced surveillance
From 2006 to 2009 inclusive, 322 cases of RRV 
with onset in the off-season in the two regions, 
were notified on WANIDD. Of these, 67 (20.8%) 
had enhanced surveillance from which it could 
be ascertained that 44/67 cases (65.7%) occurred 
Figure 1: Notification rate Ross River, Perth Metropolitan and Peel regions, by month and year
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Figure 2: Notification rates for off-season Ross 
River virus infections,* Perth Metropolitan 
and Peel regions, by onset year
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in the Perth Metropolitan or Peel region in June 
to September, whilst 23 were reclassified as either 
seasonal exposure (10), non-Perth Metropolitan/
Peel exposure (9) or both (4). Of the 1,416 RRV 
cases that were notified on WANIDD as seasonal 
in the two regions from 2006–2009, 455 (32%) had 
enhanced surveillance. Seventeen (3.7%) of these 
were reclassified as off-season using enhanced sur-
veillance data; and 5 cases originally classified as 
non-metropolitan were determined by enhanced 
surveillance to be in Perth Metropolitan or Peel.
Laboratory testing
Between 1 January 2002 and 30 June 2012, 
PathWest notified 7.6% of all RRV notifications in 
the Perth Metropolitan and 14.2% from the Peel 
region, while 19.7% and 4.3% respectively came 
from SJGP. While peak periods of testing occurred 
during the season, testing continued at high num-
bers during the off-season (Figure 3). A similar pat-
tern of testing occurred for Peel (data not shown). 
The mean number of off-season RRV tests did not 
differ significantly between the years of higher off-
season notifications (2006–2009) compared with 
the remainder (573.3 per year vs 484.6 per year, 
P=0.25). Off-season testing increased from 2004 
onwards compared with 2002 and 2003 (mean 
569.0 per year vs 324.5 per year, P<0.001).
In the two regions of interest, the proportion of 
IgM tests that were positive showed some seasonal 
variation with peaks in the summer months, while 
a higher proportion of tests were positive in the 
off-season from 2007 to 2009, particularly from 
SJGP (Figure 4). During the off-seasons from 
2002 to 2011, the proportion of positive tests from 
SJGP ranged from 0.4% in 2002 to 15% in 2009. 
For PathWest the proportion of positive test results 
ranged from 0% in 2003 to 6% in 2007.
Between 1 January 2002 and 31 August 2012, 
8,428 RRV IFA IgM tests were performed at 
PathWest from the two regions; 1,979 during the 
off-season and 6,449 during the season. Of these, 
142 (7.2%) were positive during the off-season and 
1,044 (16.1%) during the season. Sixty-six patients 
tested during the off-season and 563 tested during 
the season had more than 1 sample at intervals 
suitable for patient classification and IgM assess-
ment (Table 2).
Figure 3: Total number of IgM tests performed by PathWest and St John of God Pathology and 
notification rate for Ross River virus infection, Metropolitan Perth, January 2002 to June 2012, by 
month and year of specimen collection date
0
50
100
150
200
250
300
0
100
200
300
400
500
600
Ja
n
M
ay
S
ep Ja
n
M
ay
S
ep Ja
n
M
ay
S
ep Ja
n
M
ay
S
ep Ja
n
M
ay
S
ep Ja
n
M
ay
S
ep Ja
n
M
ay
S
ep Ja
n
M
ay
S
ep Ja
n
M
ay
S
ep Ja
n
M
ay
S
ep Ja
n
M
ay
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
R
at
e 
pe
r 1
00
,0
00
 p
op
ul
at
io
n
N
um
be
r o
f l
ab
or
at
or
y 
te
st
s
Year and month
Number of Laboratory tests
Notification rate
CDI Vol 38 No 2 2014 E119
 Original articles
Fi
gu
re
 4
: P
er
 c
en
t o
f R
os
s 
R
iv
er
 v
ir
us
 I
gM
 te
st
s 
th
at
 w
er
e 
po
si
ti
ve
, P
er
th
 M
et
ro
po
lit
an
 re
gi
on
, J
an
ua
ry
 2
00
2 
to
 Ju
ne
 2
01
2,
 b
y 
m
on
th
, y
ea
r o
f s
pe
ci
m
en
 
co
lle
ct
io
n 
da
te
 a
nd
 la
bo
ra
to
ry
0510152025303540
Jan
Jul
Jan
Jul
Jan
Jul
Jan
Jul
Jan
Jul
Jan
Jul
Jan
Jul
Jan
Jul
Jan
Jul
Jan
Jul
Jan
Jul
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
IgM per cent positive
Ye
ar
 a
nd
 m
on
th
P
riv
at
e 
la
bo
ra
to
ry
 %
 Ig
M
 p
os
iti
ve
P
at
hW
es
t %
 Ig
M
 p
os
iti
ve
E120 CDI Vol 38 No 2 2014
Original articles 
During the off-season the positive predictive value 
(PPV) for an IgM positive, HI<40 result was 
39.3%, and for an IgM positive, HI≥40 result the 
PPV was 84.2%. During the season the PPV for 
IgM positive, HI<40 result was 81.1%, and for an 
IgM positive, HI≥40 result the PPV was 92.7%.
During the off-season, 25 (17.4%) of the 
142 PathWest RRV test results meeting the case 
definition for notification were IgM positive, 
HI<40. During the season, 177 (17.0 %) of the 
1044 PathWest RRV test results meeting the case 
definition for notification were IgM positive, 
HI<40.
Between 1 January 2002 and 31 of August 2012, 
19,177 RRV EIA IgM tests were performed at 
SGJP for the two regions; 4,569 during the off-
season and 14,608 during the season. Of these, 
197 (4.3%) were positive during the off-season and 
1,062 (7.3%) during the season. Eighty-one patients 
tested during the off-season and 366 tested during 
the season had more than 1 sample at intervals 
suitable for patient classification and IgM assess-
ment (Table 3).
During the off-season the PPV for an IgM posi-
tive, IgG negative result was 4.0%, and 60.0% for 
an IgM positive, IgG positive result. During the 
season the PPV for IgM positive, IgG negative 
result was 24.6%, and 60.7% for an IgM positive, 
IgG positive result the PPV.
During the off-season, 150 (76.1%) of the 197 SJGP 
RRV test results meeting the case definition for 
notification were IgM positive, IgG negative. 
During the season, 689 (64.9%) of the 1,062 SJGP 
test results meeting the case definition for notifica-
tion were IgM positive, IgG negative.
Of the patients from PathWest classified as having 
genuine IgM, 54.4% had serological evidence of 
acute infection (either seroconversion or rising HI 
titres), the remaining having stable HI titres.
Notification practices of the laboratories
SJGP and PathWest contributed data to the study 
while the others did not, but all pathology labora-
tories doing their own RRV testing provided infor-
mation about their notification practices.
PathWest notifies all IgM positive test results. For 
the period 2006 to 2009, PathWest notified 16.6% 
of notifications from Perth Metropolitan and Peel 
regions in the off-season and 30.3% of the notifica-
tions for the remaining months.
All private laboratories in Western Australia use 
the commercial EIA assay, but notification prac-
tices varied.
SJGP does not always notify IgM positive test 
results amongst individuals with known autoim-
mune disease or viral infections known to cause 
false positive test results (around one-third of 
positive IgM results). The approach was variously 
applied over time. For the period 2006 to 2009, 
SJGP notified 18.2% of the notifications from 
the Perth Metropolitan and Peel regions in the 
off-season and 14.5% of the notifications for the 
remaining months.
Table 2. Classification of positive IgM tests using immunofluorescence assay and 
haemagglutination inhibition tests where follow-up testing was performed, 1 January 2002 to 
31 August 2012
Season Off-season
Initial test result IgM positive, HI<40 IgM positive, HI≥40 IgM positive, HI<40 IgM positive, HI≥40
True positive 202 291 11 32
False positive 47 23 17 6
Total 249 314 28 38
Table 3: Classification of positive IgM enzyme immunoassay tests where follow-up testing was 
performed, 2002 to 31 August 2012
Season Off-season
Initial test result
IgM positive,  
IgG negative
IgM positive,  
IgG positive
IgM positive,
IgG negative
IgM positive,
IgG negative
True positive 82 17 3 3
False positive 252 11 71 2
Total 334 28 74 5
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Private laboratory B notifies positive IgM test 
results only when there is a positive IgG test result 
either at the time of the initial IgM test or upon 
seroconversion. For the period 2006 to 2009, this 
laboratory notified 10.1% of notifications from the 
Perth Metropolitan and Peel regions in the off-
season and 11.2% of notifications for the remain-
ing months.
Private laboratory C notifies all positive IgM test 
results. For the period 2006 to 2009, this labora-
tory notified 40.8% of notifications from the Perth 
Metropolitan and Peel regions in the off-season 
and 36% of notifications for the remaining months.
Discussion
While we were unable to explain the increase in 
off-season notifications during 2006 to 2009, we 
identified a number of challenges in interpreting 
RRV notification data, particularly in the off-
season.
We found that where follow-up tests were per-
formed on patients with their first positive IgM 
during the off-season, the PPV of an IgM positive 
test in the absence of IgG was very low regardless 
of the IgM test used. During the season, the PPV 
value for the IFA alone rose to 81.1%, while for the 
EIA it remained low.
Patients who had follow-up serology within 
the acceptable timeframe may not represent all 
patients undergoing testing. Furthermore, some 
patients may have been incorrectly classified, such 
as those with delayed seroconversion. Despite 
these limitations, it is clear that detection of IgM 
in the absence of IgG using the commercial EIA 
test should be interpreted with caution as there is 
a high chance that it is a false positive. Similarly 
the IFA-IgM test alone cannot be reliably used to 
indicate acute infection during the off-season.
If the HI titre on the initial test is ≥40 the PPV for 
the IFA/HI is over 80% regardless of the season. 
For the commercial EIA the PPV of an IgM and 
IgG positive test was around 60% regardless of the 
season, which may be acceptable for surveillance 
purposes, but should be interpreted cautiously for 
patient diagnosis.
Our findings are consistent with a study that 
found that 45% of patients with RRV IgM but not 
IgG failed to seroconvert on follow-up testing.8 A 
similar problem has been described with the EIA 
for IgM to the closely related BFV from the same 
manufacturer.9
Based on these findings, there is a very strong case 
to remove from the RRV case definition the pos-
sibility of laboratory confirmation for RRV IgM 
positive/ IgG negative test results. This would 
substantially reduce the number of notifications 
from the private laboratories; at least for those who 
notify according to the agreed case definition; but 
very few genuine positives will be lost. Removing 
the IFA-IgM only positives detected during the 
season would remove up to 14% of the genuine 
cases from PathWest.
RRV IgM antibodies usually appear within a few 
days of illness onset, so the presence of IgM anti-
body in sera is considered to be indicative of acute 
or recent infection.6 However, in most cases of 
RRV infection, IgM antibodies remain in sera for 
1 year at least.6,10 Therefore even if IgM is present 
it may not mean infection or reinfection occurred 
in the season of sampling, unless it is accompanied 
by seroconversion or a rise in IgG titre. The latter 
cannot be easily determined using the EIA tests. 
Patients with RRV may not present in the acute 
phase, but rather some time later when their symp-
toms persist, which may be during the off-season. 
If the date of symptom onset is not available, as in 
the majority of cases, the specimen date will be 
interpreted as the onset date and the cases misclas-
sified as off-season cases.
We also identified variations in reporting practice 
for single IgM positive results between laboratories 
and at different times. Some laboratories don’t 
notify these cases, despite them meeting the RRV 
case definition. Therefore the PPV of notifications 
from different laboratories differs. This is not 
problematic if there is consistency in notification 
practices over time, and if there is no geographical 
variation in coverage by the different laboratories. 
However, there are differences in the regional cov-
erage of the laboratories, making the comparison 
of notification rates between different regions dif-
ficult.
Testing data from the two laboratories did not 
reveal increased RRV testing in the off-season in 
the years 2006 to 2009. The higher rate of posi-
tive results during this time may reflect an actual 
increase in RRV incidence, but this would usually 
be accompanied by increased testing. From these 
data, there is no clear explanation for the increase 
in off-season notifications in those years.
RRV symptoms can last for up to 6 months.6 
Therefore people with persisting symptoms may 
be tested after the acute phase. Without enhanced 
surveillance, a notification of a positive RRV test 
could be wrongly classified as occurring in the 
off-season as pathology laboratories do not rou-
tinely provide the date of symptom onset. Where 
enhanced surveillance was undertaken, there were 
notifications that were thus misclassified in both 
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the off-season and during the season. This is likely 
to be due to the long duration of symptoms and the 
fact that laboratory notifications report the resi-
dential address of the case rather than their place 
of acquisition. Based on our data, if enhanced sur-
veillance was uniformly performed for off-season 
and seasonal RRV notifications, more RRV noti-
fications in the off-season would be reclassified as 
seasonal than vice versa.
The change in legislation in Western Australia 
requiring laboratory notification for notifiable 
diseases that was introduced in 2006 may explain 
the observed increase in winter cases from 2006 to 
2009. However, as this increase did not continue 
between 2010 and 2012 it is difficult to make this 
interpretation until a few more years of notifica-
tion data become available.
We identified a number of challenges in interpret-
ing RRV notification data. Much of this appears 
to be due to the low PPV of the RRV IgM test that 
is used as the basis for most notifications. At peak 
risk times and in higher risk geographical areas, 
the PPV of the IgM test results is likely to be suf-
ficiently high to enable identification of the timing 
and distribution of RRV activity, particularly if the 
IgM is accompanied by RRV-IgG. Furthermore, 
the long-term persistence of IgM is likely to be 
contributing to the over-notification of appar-
ent off-season cases where patients were actually 
infected during the preceding season. Therefore 
only large changes in disease notification rates are 
likely to be able to be interpreted reliably based in 
IgM results alone.
Finally, enhanced surveillance should remain an 
important tool for the accurate understanding of 
RRV epidemiology, particularly when notification 
data suggests a change in the distribution of RRV, 
either in time or in place, or when there are unex-
pected increases in notifications.
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